Showing 9831-9840 of 20328 results for "".
- Understanding Emotional Expressions in Autism: Clinical Implications and Strategieshttps://reachmd.com/news/understanding-emotional-expressions-in-autism-clinical-implications-and-strategies/2485370/Contrary to the longstanding assumption that basic emotions map onto universal facial markers, a comparative study of autistic and non-autistic adults identified divergent kinematic
- Study: Upadacitinib Reduces Inflammation Markers in ADhttps://reachmd.com/news/study-upadacitinib-reduces-inflammation-markers-in-ad/2485380/Upadacitinib (UPA) treatment was associated with significant reductions in biomarkers of systemic inflammation in adults with moderate-to-severe atopic dermatitis (AD), according to a poster presented at Winter Clinical 2026 in Hawaii.
- TYK2 Inhibitor Envudeucitinib Shows Durable Skin Clearance, QoL Gains: Posterhttps://reachmd.com/news/tyk2-inhibitor-envudeucitinib-shows-durable-skin-clearance-qol-gains-poster/2485378/Envudeucitinib, an investigational selective allosteric TYK2 inhibitor, showed sustained achievement of clinically meaningful treat-to-target outcomes in patients with moderate-to-severe plaque psoriasis, according to 52-week data presented at 2026 Winter Clinical
- RUS-PAT 3D Imaging: Revolutionizing Surgical and Trauma Assessmentshttps://reachmd.com/news/rus-pat-3d-imaging-revolutionizing-surgical-and-trauma-assessments/2485344/RUS-PAT offers rapid, noninvasive 3D imaging for surgical and trauma assessment by combining volumetric soft-tissue and vascular visualization with bedside spe
- Innovative Use of Genomics and AI in Respiratory Diagnostics Enhances Stewardshiphttps://reachmd.com/news/innovative-use-of-genomics-and-ai-in-respiratory-diagnostics-enhances-stewardship/2485356/A genomics–AI platform that pairs a host biomarker with a large language model improved pathogen detection in a study; investigators estimated that, if available at admission, it could have reduced inappropriate antibiotic use by more than 80%.
- Microbiome-Informed Precision Nutrition: Bridging the Gap in Metabolic Healthhttps://reachmd.com/news/microbiome-informed-precision-nutrition-bridging-the-gap-in-metabolic-health/2485346/Microbiome-informed precision nutrition is moving from concept to clinical application, offering individualized dietary guidance grounded in host–microbe interactions and metabolic-response profiling. Small randomized controlled trials and other controlled studies s
- Molecular Pathways in Adipose Inflammation: New Insights into Cardiometabolic Riskhttps://reachmd.com/news/molecular-pathways-in-adipose-inflammation-new-insights-into-cardiometabolic-risk/2485348/SAMHD1 phosphorylation links adipose mitochondrial DNA accumulation to NLRP3 inflammasome activation, driving adipose inflammation in obesity and potentially contributing to systemic metabolic dysregulation. Phosphorylation of SAMHD1 reduces its nuclease activity in
- Chronic Pancreatic Inflammation and Early Tumorigenesis: Unveiling Mechanisms and Potential Biomarkershttps://reachmd.com/news/chronic-pancreatic-inflammation-and-early-tumorigenesis-unveiling-mechanisms-and-potential-biomarkers/2485350/Chronic pancreatic inflammation drives early PDAC initiation in a mutant Kras mouse model, reframing early-detection priorities.<
- Advancements in Prostate Cancer Screening: PSA, Risk Models, and Genomic Innovationshttps://reachmd.com/news/advancements-in-prostate-cancer-screening-psa-risk-models-and-genomic-innovations/2485341/Stockholm3, paired with PSA screening, improves detection of clinically significant prostate cancer while reducing overdiagnosis and unnecessary procedures — reframing follow-up decisions after an elevated PSA.
- TYK2 Inhibitor ICP-332 Demonstrates Efficacy, Safety in ADhttps://reachmd.com/news/tyk2-inhibitor-icp-332-demonstrates-efficacy-safety-in-ad/2485331/A novel oral TYK2 inhibitor, ICP-332, demonstrated favorable safety and promising efficacy in a recent phase 2 randomized clinical trial for moderate to severe atopic dermatitis (AD). Researchers for the double-blind, placebo-co